Chemomab Posts $5.1 Million Loss, Calls Shareholders to Vote on Merger
Key Facts
Chemomab Therapeutics on November 19 reported financial and operating results for the third quarter ended September 30, 2026, alongside an update on its proposed merger with Scipher Medicine, according to a statement published by GlobeNewswire. The company posted a net loss of $5.1 million, compared with a loss of $1.7 million in the same period a year earlier. The results put liquidity and operating funding at the center of its financial position as the deal moves toward a shareholder vote. The company said a special shareholder meeting will be held on December 4 to vote on the merger. The U.S. Securities and Exchange Commission declared the deal's registration statement effective on October 30. The company expects to complete the merger in the first quarter of 2027, subject to shareholder approval and satisfaction of the remaining closing conditions.
Cash, cash equivalents and short-term bank deposits totaled $4.7 million on September 30, compared with $6.7 million on June 30, 2026. Chemomab said funding it secured in November, together with available cash, is expected to fund operations through the first quarter of 2027. That estimate places the company's stated funding horizon in the period when it is targeting completion of the merger. Closing remains subject to approval by Chemomab and Scipher shareholders and the other specified conditions. The agreement requires concurrent financing with gross proceeds of between $30 million and $50 million. In an illustrative scenario assuming $30 million is raised, the expected post-financing stakes would be 56.70% for former Scipher shareholders, 26.70% for former Chemomab shareholders and 16.60% for financing investors, before accounting for shares issued upon the exercise of warrants.
Research and development expenses rose to $3.7 million in the third quarter of 2026, from $1 million in the comparable period of 2025. The company attributed the increase primarily to recording about $2.9 million in prepaid manufacturing costs as expenses during the quarter. General and administrative expenses were $1.4 million, compared with $0.9 million a year earlier. Chemomab said the increase in that item was primarily due to costs related to the proposed merger. With expenses rising in both categories, the net loss widened to $5.1 million from $1.7 million a year earlier. The figures provide financial context for the deal as the company relies on existing and new funding to continue operations through the expected closing date.
On the clinical front, Chemomab said it and Scipher completed a Type B interaction ahead of submitting an investigational new drug application to the U.S. Food and Drug Administration for a planned Phase 2 trial of nebokitug to treat rheumatoid arthritis. It added that the agency's feedback was generally consistent with the company's development assumptions. Chemomab plans to submit an IND for the trial and expects topline results in the first half of 2028. The company linked the deal's opportunity to clinical development of the drug and Scipher's precision medicine work and partnerships with pharmaceutical and biotechnology companies. Chemomab estimated the global rheumatoid arthritis market at about $24 billion annually. These clinical plans remain subject to upcoming regulatory and financing developments.
The deal documents assign Chemomab a valuation of $48 million and Scipher a valuation of $102 million, for a total of up to $150 million before concurrent financing; Scipher's valuation could be reduced based on debt at closing. The documents also say the resulting parent company expects to change its name to Scipher Medicine Corporation and that its common stock will be listed on the Nasdaq Capital Market under the ticker SCIP after the merger is completed. In its review of the deal, Chemomab's board cited the risks of continuing independently and the cost of a Phase 3 trial for primary biliary cholangitis. The proxy document said the company had contacted 69 pharmaceutical and biotechnology companies over two and a half years without reaching a partnership that could be implemented. The document said available cash was about $8.0 million on March 31, 2026. CMMB shares closed at $1.55 in the November 18 session, after closing at $1.64 in the previous session.